Objective: To investigate the association between joint manifestations of vascular ageing (VA) and hypertension.
Methods: We used baseline (2008-2012) and follow-up data (up to 2024) from the Paris Prospective Study III, a French cohort of 10,157 participants. Prevalent and incident hypertension were determined at baseline (blood pressure ≥140/90 mmHg or on medication) and at 2, 4, 6, 8 and 10 years of follow-up (self-reported antihypertensive treatment).
Propolis is a resinous material collected by different bee species from various plant exudates and used to seal holes in honeycombs, smoothen the internal walls, embalm intruders, improve health and prevent diseases. From its -hexane extract, eight compounds were isolated and characterised as: mangiferonic acid (); 1-hydroxymangiferonic acid (), new natural product; mangiferolic acid(); 27-hydroxymangiferolic acid (), reported here for the first time as propolis constituent; 27-hydroxymangiferonic acid (); -amyrin (); -amyrin () and lupeol (). The chemical structures of the isolated compounds were elucidated using spectroscopic methods, such as 1D and 2D-NMR, mass spectrometry and comparison with previous published reports.
View Article and Find Full Text PDFObjectives: Gadopiclenol is a q = 2 pyclen gadolinium-based contrast agent (GBCA) recently approved by the Food and Drug Administration, European Medicines Agency, and other European countries. The aim of this report is to demonstrate its stability in multiple stressed in vitro conditions and in vivo, in rat kidney, while maintaining its higher relaxivity compared with conventional GBCAs on the market.
Materials And Methods: Both gadopiclenol and its chemical precursor Pi828-Gd were characterized and compared with q = 1 gadolinium (Gd) complexes.
Biallelic loss-of-function variants in STRC contribute to mild-moderate hearing loss (DFNB16). Here, we report a female patient with mild hearing loss. Exome sequencing and MLPA analysis revealed STRC biallelic inactivation due to a nonsense and a CKMT1B-STRC deletion.
View Article and Find Full Text PDFTargeted vasopeptide therapies have significantly advanced the management of pulmonary arterial hypertension (PAH). However, due to insufficient preclinical evidence regarding the involvement of the endothelin-1 (ET-1) pathway in chronic thromboembolic pulmonary hypertension (CTEPH) pathophysiology, the potential of ET-1 receptor antagonism in treating CTEPH remains uncertain. In this study, we investigated the role of the ET-1 pathway in CTEPH microvasculopathy using a multifaceted approach.
View Article and Find Full Text PDF